The MYL12A Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population targeting the MYL12A gene in the human Raji B lymphoblastoid line. This model provides a genetically disrupted loss-of-function system for studying regulatory myosin light chain 12A within an immune cell context. The polyclonal pool retains population-level heterogeneity while eliminating functional MYL12A protein expression, enabling robust analysis of actomyosin-dependent processes without the clonal artifacts often associated with single-cell-derived lines. Researchers can utilize these cells to dissect the molecular mechanisms by which nonmuscle myosin II activity is governed in B-cell physiology and pathology.
Raji cells are an extensively characterized, Epstein?CBarr virus-immortalized lymphoblastoid line derived from a Burkitt lymphoma patient. They constitutively express surface B-cell markers, including CD19, CD20, and CD22, and retain functional capacities for antibody production and antigen presentation. Their transformed yet differentiated phenotype makes them a widely adopted model for studying B-cell malignancies, adaptive immunity, and lymphomagenesis. The EBV-immortalized state drives constitutive activation of multiple signaling cascades, some of which intersect with cytoskeletal regulators, thereby offering a unique background to examine how MYL12A-dependent mechanical outputs influence lymphoma cell behavior.
MYL12A encodes the regulatory myosin light chain 12A, a critical subunit of nonmuscle myosin II that controls actomyosin contractility in response to upstream stimuli. The MYL12A protein is phosphorylated by kinases such as MLCK and ROCK downstream of RhoA, Ca2+/calmodulin, and various cytokines and growth factors. Phosphorylated MYL12A activates the ATPase activity of myosin II heavy chains, thereby promoting actin filament sliding and generating contractile force. This myosin II activation is essential for focal adhesion turnover, cell migration, and cytokinesis. MYL12A directly interacts with myosin heavy chain, actin, calmodulin, and its paralog MYL12B, integrating signals that coordinate cytoskeletal remodeling with cellular behavior.
In the Raji host background, disruption of MYL12A is expected to profoundly impair actomyosin dynamics that underlie B-cell adhesion, migration, and immune synapse formation. Lymphoma cells rely on RhoA/ROCK-driven myosin II activation for transendothelial migration and invasive motility??processes critical for metastasis and disease progression. The knockout model thus permits direct investigation of how loss of regulatory light chain phosphorylation alters cortical tension, integrin-mediated attachment, and the ability of malignant B-cells to navigate microenvironmental niches. Moreover, because Raji cells are used as antigen-presenting cells, MYL12A depletion may uncover novel links between cytoskeletal machinery and adaptive immune signaling.
These polyclonal knockout cells are ideally suited for a range of targeted investigations in cancer biology, immunology, and drug discovery. Researchers can employ western blotting and phospho-specific antibodies to confirm MYL12A ablation and assess compensatory MYL12B expression, while immunofluorescence and confocal microscopy visualize F-actin and myosin II organization. Functional assays such as transwell migration can quantify changes in chemotaxis, and RhoA activation assays directly probe upstream pathway activity. Co-immunoprecipitation experiments with myosin heavy chain can verify disrupted myosin complex assembly, and flow cytometry for integrin surface expression examines adhesion receptor dynamics. For further technical details or custom applications, please contact Ascent Research.
